vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and FIRST FINANCIAL CORP (THFF). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $70.5M, roughly 1.1× FIRST FINANCIAL CORP). FIRST FINANCIAL CORP runs the higher net margin — 30.4% vs -9.6%, a 40.0% gap on every dollar of revenue. On growth, FIRST FINANCIAL CORP posted the faster year-over-year revenue change (14.1% vs -16.8%). Over the past eight quarters, FIRST FINANCIAL CORP's revenue compounded faster (20.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

First American Financial Corporation is an American financial services company which provides title insurance and settlement services to the real estate and mortgage industries.

BIOX vs THFF — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.1× larger
BIOX
$77.6M
$70.5M
THFF
Growing faster (revenue YoY)
THFF
THFF
+31.0% gap
THFF
14.1%
-16.8%
BIOX
Higher net margin
THFF
THFF
40.0% more per $
THFF
30.4%
-9.6%
BIOX
Faster 2-yr revenue CAGR
THFF
THFF
Annualised
THFF
20.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
THFF
THFF
Revenue
$77.6M
$70.5M
Net Profit
$-7.4M
$21.5M
Gross Margin
46.8%
Operating Margin
9.3%
37.4%
Net Margin
-9.6%
30.4%
Revenue YoY
-16.8%
14.1%
Net Profit YoY
-20.2%
32.1%
EPS (diluted)
$-0.12
$1.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
THFF
THFF
Q4 25
$70.5M
Q3 25
$77.6M
$65.8M
Q2 25
$63.1M
Q1 25
$60.6M
$62.5M
Q4 24
$98.8M
$61.8M
Q3 24
$93.3M
$58.4M
Q2 24
$49.2M
Q1 24
$84.0M
$48.4M
Net Profit
BIOX
BIOX
THFF
THFF
Q4 25
$21.5M
Q3 25
$-7.4M
$20.8M
Q2 25
$18.6M
Q1 25
$-1.6M
$18.4M
Q4 24
$605.2K
$16.2M
Q3 24
$-6.2M
$8.7M
Q2 24
$11.4M
Q1 24
$9.8M
$10.9M
Gross Margin
BIOX
BIOX
THFF
THFF
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
THFF
THFF
Q4 25
37.4%
Q3 25
9.3%
39.2%
Q2 25
36.2%
Q1 25
1.5%
38.1%
Q4 24
14.5%
32.4%
Q3 24
2.5%
17.9%
Q2 24
27.6%
Q1 24
15.7%
27.2%
Net Margin
BIOX
BIOX
THFF
THFF
Q4 25
30.4%
Q3 25
-9.6%
31.6%
Q2 25
29.5%
Q1 25
-2.6%
29.5%
Q4 24
0.6%
26.3%
Q3 24
-6.6%
15.0%
Q2 24
23.1%
Q1 24
11.6%
22.6%
EPS (diluted)
BIOX
BIOX
THFF
THFF
Q4 25
$1.81
Q3 25
$-0.12
$1.75
Q2 25
$1.57
Q1 25
$-0.02
$1.55
Q4 24
$0.00
$1.37
Q3 24
$-0.10
$0.74
Q2 24
$0.96
Q1 24
$0.14
$0.93

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
THFF
THFF
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
$188.2M
Stockholders' EquityBook value
$288.3M
$650.9M
Total Assets
$734.9M
$5.8B
Debt / EquityLower = less leverage
0.29×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
THFF
THFF
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Total Debt
BIOX
BIOX
THFF
THFF
Q4 25
$188.2M
Q3 25
$170.5M
Q2 25
$122.7M
Q1 25
$124.9M
Q4 24
$28.1M
Q3 24
$30.5M
Q2 24
$108.6M
Q1 24
$58.6M
Stockholders' Equity
BIOX
BIOX
THFF
THFF
Q4 25
$650.9M
Q3 25
$288.3M
$622.2M
Q2 25
$587.7M
Q1 25
$345.0M
$571.9M
Q4 24
$346.3M
$549.0M
Q3 24
$346.0M
$566.0M
Q2 24
$530.7M
Q1 24
$348.5M
$520.8M
Total Assets
BIOX
BIOX
THFF
THFF
Q4 25
$5.8B
Q3 25
$734.9M
$5.7B
Q2 25
$5.6B
Q1 25
$798.2M
$5.5B
Q4 24
$835.2M
$5.6B
Q3 24
$827.3M
$5.5B
Q2 24
$4.9B
Q1 24
$836.1M
$4.9B
Debt / Equity
BIOX
BIOX
THFF
THFF
Q4 25
0.29×
Q3 25
0.27×
Q2 25
0.21×
Q1 25
0.22×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
0.20×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
THFF
THFF
Operating Cash FlowLast quarter
$14.4M
$90.4M
Free Cash FlowOCF − Capex
$86.4M
FCF MarginFCF / Revenue
122.5%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$144.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
THFF
THFF
Q4 25
$90.4M
Q3 25
$14.4M
$26.9M
Q2 25
$12.7M
Q1 25
$23.3M
$21.1M
Q4 24
$-5.4M
$60.4M
Q3 24
$5.2M
$23.3M
Q2 24
$8.8M
Q1 24
$-17.4M
$12.4M
Free Cash Flow
BIOX
BIOX
THFF
THFF
Q4 25
$86.4M
Q3 25
$25.8M
Q2 25
$11.6M
Q1 25
$20.5M
Q4 24
$54.3M
Q3 24
$19.5M
Q2 24
$8.4M
Q1 24
$11.5M
FCF Margin
BIOX
BIOX
THFF
THFF
Q4 25
122.5%
Q3 25
39.2%
Q2 25
18.4%
Q1 25
32.8%
Q4 24
87.8%
Q3 24
33.5%
Q2 24
17.2%
Q1 24
23.7%
Capex Intensity
BIOX
BIOX
THFF
THFF
Q4 25
5.6%
Q3 25
1.7%
Q2 25
1.8%
Q1 25
0.9%
Q4 24
9.9%
Q3 24
6.5%
Q2 24
0.7%
Q1 24
2.0%
Cash Conversion
BIOX
BIOX
THFF
THFF
Q4 25
4.21×
Q3 25
1.29×
Q2 25
0.68×
Q1 25
1.14×
Q4 24
-8.85×
3.72×
Q3 24
2.67×
Q2 24
0.77×
Q1 24
-1.78×
1.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons